Home/Pipeline/Tyruko® (biosimilar natalizumab)

Tyruko® (biosimilar natalizumab)

Multiple Sclerosis

ApprovedActive

Key Facts

Indication

Multiple Sclerosis

Phase

Approved

Status

Active

Company

Polpharma Biologics

About Polpharma Biologics

Polpharma Biologics, originally founded in 2012 and headquartered in the Netherlands, has undergone a significant transformation, splitting into two independent entities. The remaining Polpharma Biologics is now a pure-play biosimilars developer with a strategic base in Zug, Switzerland, focusing on building a targeted pipeline and forging global partnerships. The company has a commercial-stage asset, Tyruko®, and leverages an agile development model aimed at accelerating biosimilar approval and market access. Its former large-scale manufacturing and CDMO operations now reside with the separate company, Rezon Bio, based in Poland.

View full company profile

Therapeutic Areas

Ophthalmology Neurology Immunology Autoimmune Diseases

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active